Table 1. Clinical characteristics of patients in the PAF and non-PAF groups.
| Variables | Total | PAF | non-PAF | P Value |
|---|---|---|---|---|
| Patients, n (%) | 118 | 73 (61.8) | 45 (38.1) | |
| Male sex, n (%) | 102(86.4) | 61 (83.5) | 41 (91.1) | 0.28 |
| Age, years (IQR) | 58 (50–62) | 59 (49.5–62) | 58 (51–62) | 0.98 |
| BMI, kg/m2 (IQR) | 23.8 (21.6–26.5) | 23.8 (21.7–26.7) | 23.9(21.3–26.1) | 0.88 |
| Duration of AF, months (IQR) | 26 (7–72) | 36(6.5–72) | 24 (7–14) | 0.46 |
| Hypertension, n (%) | 37 (31.3) | 23 (31.5) | 14 (31.1) | 1 |
| Diabetes mellitus, n (%) | 11(9.3) | 7(9.6) | 4(8.9) | 1 |
| Stroke, n (%) | 10(8.5) | 5(6.8) | 5(11.1) | 0.50 |
| History of TCM, n (%) | 9(7.6) | 5(6.8) | 4(8.9) | 0.73 |
| Pre-ablation anti-arrhythmic drugs | ||||
| Class Ⅰ AAD, n (%) | 46(39.0) | 37(50.7) | 9(20.0) | <0.001* |
| Class Ⅲ AAD, n (%) | 2(1.7) | 1(1.4) | 1(2.2) | 1 |
| βblocker, n (%) | 50(42.4) | 27(37.0) | 23(51.1) | 0.18 |
| ACEI/ARB, n (%) | 34(28.8) | 18(24.7) | 16(35.6) | 0.22 |
| Statin, n (%) | 25(21.2) | 12(16.4) | 13(28.9) | 0.16 |
| LV ejection fraction, % (IQR) | 67(61.8–71.0) | 69(65–72) | 64(59–68) | <0.0001* |
| Left atrial anteroposterior echocardiographic dimension, mm (IQR) | 41(37–44) | 40(36–43) | 42(39–46) | 0.008* |
| NT proBNP, pg/ml (IQR) | 118(51–382) | 67(30–135) | 391(223–818) | <0.0001* |
| Recurrent patients, n (%) | 42(35.6) | 23(31.5) | 19(42.2) | 0.23 |
| Recurrence time, months (IQR) | 6.5(3.2–9.7) | 7.0(4.0–10.5) | 6.0(3.0–9.0) | 0.75 |
Data are n (%), and median (IQR; 25%―75% interquartile range).
* significant difference
AAD, anti-arrhythmic drug; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BMI, body mass index; LV, left ventricle; non-PAF, non-paroxysmal atrial fibrillation; PAF, paroxysmal atrial fibrillation; TCM, tachycardia-induced cardiomyopathy